Parkinson disease: An update

American Family Physician

Volumn 87, Issue 4, 2013, Pages 267-273

  Gazewood, John D ^a   Richards, D Roxanne ^b   Clebak, Karl ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b MedStar Physician Partners at St Clement's   (United States)

^c Lake Monticello Primary Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; APOMORPHINE; BENZATROPINE; BOTULINUM TOXIN A; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DESIPRAMINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLYCOPYRRONIUM BROMIDE; LISURIDE; MACROGOL; MACROGOL 3350; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; OLANZAPINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SILDENAFIL; TOLCAPONE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ADJUVANT THERAPY; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BRAIN DEPTH STIMULATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEATH; DEMENTIA; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ECHOCARDIOGRAPHY; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; ERYTHROMELALGIA; FATIGUE; FOLLOW UP; FRACTURE; HALLUCINATION; HEART MUSCLE FIBROSIS; HUMAN; HYPERSALIVATION; HYPOTENSION; IMPULSE CONTROL DISORDER; INFECTION; INSOMNIA; KIDNEY FUNCTION; LIFE EXPECTANCY; LIVEDO RETICULARIS; LIVER TOXICITY; LUNG FIBROSIS; MENTAL DISEASE; MORTALITY; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); NAUSEA; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCUPATIONAL THERAPY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHYSIOTHERAPY; POLYSOMNOGRAPHY; PROGNOSIS; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED STUDY (TOPIC); RISK FACTOR; SEROTONIN SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SOMNOLENCE; SPEECH THERAPY; THORAX RADIOGRAPHY; TREMOR; VOMITING;

ANTIPARKINSON AGENTS; COMBINED MODALITY THERAPY; DEEP BRAIN STIMULATION; DIAGNOSIS, DIFFERENTIAL; HUMANS; OCCUPATIONAL THERAPY; PARKINSON DISEASE; PHYSICAL THERAPY MODALITIES; PROGNOSIS; SPEECH THERAPY;

EID: 84874913947     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009;72(21 suppl 4): S1-S136.
2. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord. 2010;16 (2):79-84.
3. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-535.
4. Scottish Intercollegiate Guidelines Network. Diagnosis and Pharmacological Management of Parkinson's disease: A National Clinical Guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; January 2010. http://www.sign.ac.uk/pdf/sign113.pdf. Accessed March 8, 2011.
5. Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord. 2009;24(16):2379-2385.
6. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry. 2002;73(5):529-534.
7. Crawford P, Zimmerman EE. Differentiation and diagnosis of tremor. Am Fam Physician. 2011;83(6):697-702.
8. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. 2006;5(1):75-86.
9. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):968-975.
10. Rao G, Fisch L, Srinivasan S, et al. Does this patient have Parkinson disease? JAMA. 2003;289(3):347-353.
11. The National Collaborating Centre for Chronic Conditions. Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. London: Royal College of Physicians; 2006. http://www.nice.org.uk/nicemedia/live/10984/30087/30087.pdf. Accessed March 8, 2011.
12. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017-1022.
13. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology. 2008;70(16 pt 2):1423-1430.
14. de Lau LM, Schipper CM, Hofman A, Koudstaal PJ, Breteler MM. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005; 62(8):1265-1269.
15. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidencebased review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002; 58 (1): 11-17.
16. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev. 2008;(2):CD006564.
17. Caslake R, Macleod A, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease. Cochrane Database Syst Rev. 2009;(4):CD006661.
18. van Hilten JJ, Ramaker CC, Stowe R, Ives NJ. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease. Cochrane Database Syst Rev. 2007;(4):CD003634.
19. Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson's disease. Neurology. 2001;57(5):790-794.
20. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2006;67(2):299]. Neurology. 2006;66(7):976-982.
21. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fuctuations and dyskinesia (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-995.
22. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2004;(4):CD004554.
23. Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev. 2010;(7): CD007166.
24. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011; 68 (2): 165-171.
25. Weaver FM, Follett K, Stern M, et al.; CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73.
26. Deuschl G, Schade-Brittinger C, Krack P, et al.; German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease [published correction appears in N Engl J Med. 20 06;355 (12):1289]. N Engl J Med. 2006;355(9):896-908.
27. Schiftto G, Friedman JH, Oakes D, et al.; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008;71(7):481-485.
28. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74(11):924-931.
29. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen J.P. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology. 2006;67(5):853-858.
30. Sixel-Döring F, Trautmann E, Mollenhauer B, Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology. 2011;77 (11):1048-1054.
31. Schenck CH, Mahowald MW. Rapid eye movement sleep parasomnias. Neurol Clin. 2005; 23 (4): 1107-1126.
32. Arbouw ME, Movig KL, Koopmann M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology. 2010;74(15):1203-1207.
33. Hely MA, Morris JG, Reid WG, Traffcante R. Sydney Multicenter Study of Parkinson's Disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190-199.
34. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996-1002.
35. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72(10):886-892.